Biodexa Pharmaceuticals Plc (5MP0.SG)

0,8500 0,0000 (0,00%) Börsenschluss: 08:18AM CEST

Biodexa Pharmaceuticals Plc

1 Caspian Point
Caspian Way
Cardiff CF10 4DQ
United Kingdom
44 29 2048 0180
https://www.biodexapharma.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 21

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stephen A. Stamp	CEO, CFO, Company Secretary & Director	295,35k	N/A	1962
Dr. Dmitry Zamoryakhin M.D.	Chief Scientific Officer & Chief Medical Officer	279,36k	N/A	1980
Dr. Daniel Palmer MBA, Ph.D.	Vice President of Technology	N/A	N/A	N/A
Ms. Nicola Tuckwell	VP & Head of Clinical Operations	N/A	N/A	N/A
Ms. Fiona Sharp	Group Financial Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Corporate Governance

Biodexa Pharmaceuticals Plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.